These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3975872)

  • 1. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
    Bernat A; Vallée E; Maffrand JP; Roncucci R
    Thromb Res; 1985 Jan; 37(2):279-85. PubMed ID: 3975872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations.
    Millet J; Theveniaux J; Pascal M
    Thromb Res; 1987 Jan; 45(2):123-33. PubMed ID: 3563978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of platelets in experimental venous thrombosis in the rat.
    Herbert JM; Bernat A; Maffrand JP
    Blood; 1992 Nov; 80(9):2281-6. PubMed ID: 1421399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
    Herbert JM; Bernat A; Samama M; Maffrand JP
    Thromb Haemost; 1996 Jul; 76(1):94-8. PubMed ID: 8819259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
    Hanson SR; Harker LA; Bjornsson TD
    J Clin Invest; 1985 May; 75(5):1591-9. PubMed ID: 3923041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic effect of TRK-100, a novel, stable PGI2 analogue.
    Umetsu T; Murata T; Tanaka Y; Osada E; Nishio S
    Jpn J Pharmacol; 1987 Jan; 43(1):81-90. PubMed ID: 3553683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats.
    Ohtani A; Murakami J; Hirano-Wakimoto A
    Eur J Pharmacol; 1997 Jul; 330(2-3):151-6. PubMed ID: 9253948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticlopidine as an experimental antithrombotic agent.
    Vallée E; Maffrand JP; Bernat A; Delebassée D; Tissinier A
    Agents Actions Suppl; 1984; 15():50-9. PubMed ID: 6592945
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats.
    Morishita K; Wada M; Kumada T; Tanaka T; Tomikawa M; Iwamoto M
    Thromb Res; 1991 Aug; 63(3):373-84. PubMed ID: 1957278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of platelets with subendothelium in rats treated with PCA-4230, a new antithrombotic agent. Effect of PCA-4230 on experimental thrombosis.
    Gutiérrez Díaz JA; Tolón RM; Sunkel C; Priego JG; Ortega MP
    Haemostasis; 1992; 22(4):202-10. PubMed ID: 1468723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
    de Gaetano G; Bertelé V
    Agents Actions; 1984 Jan; 14(1):109-12. PubMed ID: 6702507
    [No Abstract]   [Full Text] [Related]  

  • 14. Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.
    Ashida S; Sakuma K; Abiko Y
    Thromb Res; 1980 Mar; 17(5):663-71. PubMed ID: 7385100
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (EGb 761).
    Kim YS; Pyo MK; Park KM; Park PH; Hahn BS; Wu SJ; Yun-Choi HS
    Thromb Res; 1998 Jul; 91(1):33-8. PubMed ID: 9700851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
    Weichert W; Pauliks V; Breddin HK
    Haemostasis; 1983; 13(1):61-71. PubMed ID: 6132858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.
    Cattaneo M; Winocour PD; Somers DA; Groves HM; Kinlough-Rathbone RL; Packham MA; Mustard JF
    Thromb Res; 1985 Jan; 37(1):29-43. PubMed ID: 3983900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and combined effects of a thromboxane receptor antagonist and different antithrombotic agents in a rat microcirculatory thrombosis model.
    Giedrojc J; Fellier H; Breddin HK
    Haemostasis; 1992; 22(6):322-9. PubMed ID: 1335951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
    Tuong CC; Ferrand C; Aubert D; Loubrie JC; Tuong A
    Biochem Pharmacol; 1982 Mar; 31(6):1147-50. PubMed ID: 7200772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.